Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 14/20 | 0.48 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.47 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.47 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.42 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL171905 | 0.87 | PIK3CA (0.52) | RIPK1PIK3CAPIK3CDPIK3CG | |
| SCHEMBL799248 | 0.87 | PIK3CA (0.48) | RIPK1PIK3CAPIK3CDPIK3CG | |
| SCHEMBL799159 | 0.86 | PIK3CG (0.47) | PIK3CAPIK3CDPIK3CGMEN1PABPC1 | |
| SCHEMBL799302 | 0.83 | RIPK1 (0.49) | RIPK1PIK3CA | |
| SCHEMBL798697 | 0.83 | PIK3CD (0.43) | RIPK1PIK3CAPIK3CDPIK3CGCSNK1D | |
| SCHEMBL799281 | 0.80 | KMT2A (0.49) | PIK3CAPIK3CGMEN1PABPC1KMT2A | |
| SCHEMBL12664457 | 0.79 | PIK3CA (0.56) | RIPK1PIK3CAPIK3CDPIK3CGCSNK1D | |
| SCHEMBL172085 | 0.76 | ABL1 (0.49) | PIK3CGMEN1PABPC1KMT2A | |
| SCHEMBL798968 | 0.75 | PIK3CG (0.60) | PIK3CAPIK3CDPIK3CG | |
| SCHEMBL798733 | 0.73 | PIK3CG (0.61) | PIK3CAPIK3CDPIK3CGMEN1PABPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071475-A1 | UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-20120071475-A1 | UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071475-A1 | UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY | MTOR, STAT3, SLC14A1 | RIPK1 1673/4885PIK3CA 15/4885PIK3CD 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.